Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 4 (2007), Issue 3 (March)

1. Tumor specific phage particles promote tumor regression in a mouse melanoma model.
   Cancer Immunol Immunother, 56(5): 677-87. [Abstract] [Full-text]
2. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.
   Cancer Immunol Immunother, 56(5): 709-17. [Abstract] [Full-text]
3. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells.
   Cancer Immunol Immunother, 56(5): 659-75. [Abstract] [Full-text]
4. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
   BMC Cancer, 7: 34. [Abstract] [Full-text]
5. Ambient UV, personal sun exposure and risk of multiple primary melanomas.
   Cancer Causes Control, 18(3): 295-304. [Abstract] [Full-text]
6. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases.
   Cancer Lett, 248(1): 68-80. [Abstract] [Full-text]
7. Primary malignant melanoma of the esophagus with multiple esophageal lesions.
   Nat Clin Pract Gastroenterol Hepatol, 4(3): 171-4. [Abstract] [Full-text]
8. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
   J Dtsch Dermatol Ges, 5(3): 190-6. [Abstract] [Full-text]
9. Novel treatment strategies for malignant melanoma: a new beginning?
   Crit Rev Oncol Hematol, 62(1): 16-22. [Abstract] [Full-text]
10. TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma.
    Int J Cancer, 120(9): 1935-41. [Abstract] [Full-text]
11. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation.
    Int J Cancer, 120(9): 1899-908. [Abstract] [Full-text]
12. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
    J Dermatol Sci, 46(1): 11-20. [Abstract] [Full-text]
13. The use of tissue inhibitors of matrix metalloproteinases to increase the efficacy of a tumor necrosis factor/interferon gamma antitumor therapy.
    Cancer Gene Ther, 14(4): 372-9. [Abstract] [Full-text]
14. Putative cancer stem cells in cutaneous malignancies.
    Exp Dermatol, 16(4): 297-301. [Abstract] [Full-text]
15. Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors.
    Glycobiology, 17(4): 367-73. [Abstract] [Full-text]
16. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
    J Invest Dermatol, 127(4): 900-5. [Abstract] [Full-text]
17. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells.
    J Invest Dermatol, 127(4): 906-14. [Abstract] [Full-text]
18. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
    Cancer Res, 67(6): 2840-8. [Abstract] [Full-text]
19. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
    Cancer Res, 67(6): 2632-42. [Abstract] [Full-text]
20. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
    J Clin Oncol, 25(9): 1129-34. [Abstract] [Full-text]
21. Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature.
    Am J Surg, 193(4): 493-7. [Abstract] [Full-text]
22. Pigmented Bowen's disease of the finger mimicking malignant melanoma.
    Arch Iran Med, 10(2): 255-7. [Abstract] [Full-text]
23. Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO cells.
    Ann Biomed Eng, 35(4): 605-14. [Abstract] [Full-text]
24. Loss of maspin expression contributes to a more invasive potential in malignant melanoma.
    Pigment Cell Res, 20(2): 112-9. [Abstract] [Full-text]
25. Epigenetic events in malignant melanoma.
    Pigment Cell Res, 20(2): 92-111. [Abstract] [Full-text]
26. Molecular markers of circulating melanoma cells.
    Pigment Cell Res, 20(2): 80-91. [Abstract] [Full-text]
27. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
    Cancer Chemother Pharmacol, 59(6): 749-57. [Abstract] [Full-text]
28. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
    Cell Death Differ, 14(4): 818-29. [Abstract] [Full-text]
29. Targeting Nodal in malignant melanoma cells.
    Expert Opin Ther Targets, 11(4): 497-505. [Abstract] [Full-text]
30. Digital dermoscopy in clinical practise: a three-centre analysis.
    Skin Res Technol, 13(2): 133-42. [Abstract] [Full-text]
31. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor.
    Nat Immunol, 8(4): 398-408. [Abstract] [Full-text]
32. Natural history of invasive cutaneous melanoma in Styria, Austria 2001-2003.
    J Dtsch Dermatol Ges, 5(4): 293-9. [Abstract] [Full-text]
33. Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.
    Oncogene, 26(13): 1954-8. [Abstract] [Full-text]
34. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.
    BMC Med Genet, 8: 10. [Abstract] [Full-text]
35. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
    Mod Pathol, 20(4): 416-26. [Abstract] [Full-text]
36. Reprogramming metastatic tumour cells with embryonic microenvironments.
    Nat Rev Cancer, 7(4): 246-55. [Abstract] [Full-text]
37. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma.
    J Mol Diagn, 9(2): 178-83. [Abstract] [Full-text]
38. Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment?
    J Cutan Pathol, 34(4): 301-8. [Abstract] [Full-text]
39. Histological evolution of lentiginous melanoma: a report of five new cases.
    J Cutan Pathol, 34(4): 296-300. [Abstract] [Full-text]
40. Detection of tyrosinase mRNA in the sentinel lymph nodes of melanoma patients is not a predictor of short-term disease recurrence.
    Mod Pathol, 20(4): 427-34. [Abstract] [Full-text]
41. SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53.
    J Biol Chem, 282(13): 9902-13. [Abstract] [Full-text]
42. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
    Am J Ophthalmol, 143(4): 705-7. [Abstract] [Full-text]
43. Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.
    Biochem Biophys Res Commun, 356(2): 438-43. [Abstract] [Full-text]
44. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma.
    Cancer Lett, 249(2): 188-97. [Abstract] [Full-text]
45. Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series.
    Ann Oncol, 18(4): 789-94. [Abstract] [Full-text]
46. Asymptomatic primary malignant melanoma of the esophagus.
    Onkologie, 30(4): 206-8. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.